Investigating how glucagon affects kidney function in healthy males
Renal Extraction of Glucagon and Renal Effects of Glucagon
This study is testing how glucagon affects kidney function in healthy men aged 20 to 60 years to see if it helps the kidneys work better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 20 Years to 60 Years |
| Sex | Male |
| Sponsor | Bispebjerg Hospital Academic / other |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06498063 on ClinicalTrials.gov |
What this trial studies
This crossover study aims to explore the effects of glucagon on kidney function in healthy males aged 20-60 years. It will assess whether glucagon regulates kidney function through mechanisms such as renal plasma flow, glomerular filtration rate, and renal salt excretion. Participants will undergo a constant glucagon infusion in a placebo-controlled setting, with each subject participating in three randomized trial days separated by a washout period of at least four weeks. The study seeks to clarify the physiological effects of glucagon on kidney function and its extraction by the kidneys.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy males aged 20-60 years with normal health and no significant medical history.
Not a fit: Patients with renal impairment, liver disease, or those on specific medications affecting glucose metabolism may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of glucagon's role in kidney function, potentially leading to improved treatments for kidney diseases.
How similar studies have performed: While glucagon's effects on kidney function have been previously speculated, this study represents a novel investigation into its specific mechanisms in healthy individuals.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 20-60 years * Normal health ascertained through questioning and medical examination * Normal values for blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function, and electrolytes * Informed consent Exclusion Criteria: * Immunosuppressive treatment in the preceding 12 months * Alcohol abuse * Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the investigator, may interfere with glucose metabolism * Use of lithium * Medical treatment that affects insulin secretion or cardiovascular performance measures * Liver disease (ALT \> 2x normal value) * Renal impairment (se-creatinine \> 130 μM and/or albuminuria)
Where this trial is running
Copenhagen
- Physiological laboratory, Bispebjerg Hospital, Research Unit, Clinical Physiology / Nuclear Medicine Department — Copenhagen, Denmark (Recruiting)
Study contacts
- Principal investigator: Ali Asmar, MD — Bispebjerg Hospital
- Study coordinator: Ali Asmar, MD
- Email: ali.asmar.02@regionh.dk
- Phone: 800-555-5555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.